FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306398816> ?p ?o ?g. }

• W4306398816 endingPage "2205" @default.
• W4306398816 startingPage "2205" @default.
• W4306398816 abstract "Active targeting gold nanoparticles (AuNPs) are a very promising avenue for cancer treatment with many publications on AuNP mediated radiosensitization at kilovoltage (kV) photon energies. However, uncertainty on the effectiveness of AuNPs under clinically relevant megavoltage (MV) radiation energies hinders the clinical translation of AuNP-assisted radiation therapy (RT) paradigm. The aim of this study was to investigate radiosensitization mediated by PSMA-targeted AuNPs irradiated by a 6 MV radiation beam at different depths to explore feasibility of AuNP-assisted prostate cancer RT under clinically relevant conditions. PSMA-targeted AuNPs (PSMA-AuNPs) were synthesized by conjugating PSMA antibodies onto PEGylated AuNPs through EDC/NHS chemistry. Confocal fluorescence microscopy was used to verify the active targeting of the developed PSMA-AuNPs. Transmission electron microscopy (TEM) was used to demonstrate the intracellular biodistribution of PSMA-AuNPs. LNCaP prostate cancer cells treated with PSMA-AuNPs were irradiated on a Varian 6 MV LINAC under varying depths (2.5 cm, 10 cm, 20 cm, 30 cm) of solid water. Clonogenic assays were carried out to determine the in vitro cell survival fractions. A Monte Carlo (MC) model developed on TOPAS platform was then employed to determine the nano-scale radial dose distribution around AuNPs, which was subsequently used to predict the radiation dose response of LNCaP cells treated with AuNPs. Two different cell models, with AuNPs located within the whole cell or only in the cytoplasm, were used to assess how the intracellular PSMA-AuNP biodistribution impacts the prostate cancer radiosensitization. Then, MC-based microdosimetry was combined with the local effect model (LEM) to calculate cell survival fraction, which was benchmarked against the in vitro clonogenic assays at different depths. In vitro clonogenic assay of LNCaP cells demonstrated the depth dependence of AuNP radiosensitization under clinical megavoltage beams, with sensitization enhancement ratio (SER) of 1.14 ± 0.03 and 1.55 ± 0.05 at 2.5 cm depth and 30 cm depth, respectively. The MC microdosimetry model showed the elevated percent of low-energy photons in the MV beams at greater depth, consequently resulting in increased dose enhancement ratio (DER) of AuNPs with depth. The AuNP-induced DER reached ~5.7 and ~8.1 at depths of 2.5 cm and 30 cm, respectively. Microdosimetry based LEM accurately predicted the cell survival under 6 MV beams at different depths, for the cell model with AuNPs placed only in the cell cytoplasm. TEM results demonstrated the distribution of PSMA-AuNPs in the cytoplasm, confirming the accuracy of MC microdosimetry based LEM with modelled AuNPs distributed within the cytoplasm. We conclude that AuNP radiosensitization can be achieved under megavoltage clinical radiotherapy energies with a dependence on tumor depth. Furthermore, the combination of Monte Carlo microdosimetry and LEM will be a valuable tool to assist with developing AuNP-aided radiotherapy paradigm and drive clinical translation." @default.
• W4306398816 created "2022-10-17" @default.
• W4306398816 creator A5016886878 @default.
• W4306398816 creator A5047408436 @default.
• W4306398816 creator A5047437519 @default.
• W4306398816 creator A5061658897 @default.
• W4306398816 creator A5062457091 @default.
• W4306398816 creator A5063280717 @default.
• W4306398816 creator A5063389942 @default.
• W4306398816 creator A5082403692 @default.
• W4306398816 creator A5039367670 @default.
• W4306398816 date "2022-10-17" @default.
• W4306398816 modified "2023-09-30" @default.
• W4306398816 title "Quantifying Radiosensitization of PSMA-Targeted Gold Nanoparticles on Prostate Cancer Cells at Megavoltage Radiation Energies by Monte Carlo Simulation and Local Effect Model" @default.
• W4306398816 cites W1823727300 @default.
• W4306398816 cites W1838570471 @default.
• W4306398816 cites W1871308790 @default.
• W4306398816 cites W1908199867 @default.
• W4306398816 cites W1964207055 @default.
• W4306398816 cites W1969471545 @default.
• W4306398816 cites W1992628502 @default.
• W4306398816 cites W1993906477 @default.
• W4306398816 cites W1994718961 @default.
• W4306398816 cites W2001846107 @default.
• W4306398816 cites W2020170703 @default.
• W4306398816 cites W2026812997 @default.
• W4306398816 cites W2027137358 @default.
• W4306398816 cites W2030544564 @default.
• W4306398816 cites W2034160350 @default.
• W4306398816 cites W2034483551 @default.
• W4306398816 cites W2047965481 @default.
• W4306398816 cites W2055423604 @default.
• W4306398816 cites W2056355209 @default.
• W4306398816 cites W2057300452 @default.
• W4306398816 cites W2063056001 @default.
• W4306398816 cites W2069763292 @default.
• W4306398816 cites W2078398103 @default.
• W4306398816 cites W2079931807 @default.
• W4306398816 cites W2088454897 @default.
• W4306398816 cites W2109840939 @default.
• W4306398816 cites W2128158076 @default.
• W4306398816 cites W2145238798 @default.
• W4306398816 cites W2146629016 @default.
• W4306398816 cites W2171351334 @default.
• W4306398816 cites W2189227215 @default.
• W4306398816 cites W2209394102 @default.
• W4306398816 cites W2468043060 @default.
• W4306398816 cites W2603860937 @default.
• W4306398816 cites W2606222730 @default.
• W4306398816 cites W2736497074 @default.
• W4306398816 cites W2804688853 @default.
• W4306398816 cites W2804862738 @default.
• W4306398816 cites W2900887235 @default.
• W4306398816 cites W2907371868 @default.
• W4306398816 cites W2957222805 @default.
• W4306398816 cites W2958155857 @default.
• W4306398816 cites W2961591009 @default.
• W4306398816 cites W2989161416 @default.
• W4306398816 cites W2999615033 @default.
• W4306398816 cites W2999811008 @default.
• W4306398816 cites W3086701680 @default.
• W4306398816 cites W3108978735 @default.
• W4306398816 cites W3126915368 @default.
• W4306398816 cites W3157363274 @default.
• W4306398816 cites W3158046128 @default.
• W4306398816 cites W3166166721 @default.
• W4306398816 cites W4206841660 @default.
• W4306398816 cites W4220795688 @default.
• W4306398816 cites W4229763518 @default.
• W4306398816 doi "https://doi.org/10.3390/pharmaceutics14102205" @default.
• W4306398816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36297640" @default.
• W4306398816 hasPublicationYear "2022" @default.
• W4306398816 type Work @default.
• W4306398816 citedByCount "5" @default.
• W4306398816 countsByYear W43063988162023 @default.
• W4306398816 crossrefType "journal-article" @default.
• W4306398816 hasAuthorship W4306398816A5016886878 @default.
• W4306398816 hasAuthorship W4306398816A5039367670 @default.
• W4306398816 hasAuthorship W4306398816A5047408436 @default.
• W4306398816 hasAuthorship W4306398816A5047437519 @default.
• W4306398816 hasAuthorship W4306398816A5061658897 @default.
• W4306398816 hasAuthorship W4306398816A5062457091 @default.
• W4306398816 hasAuthorship W4306398816A5063280717 @default.
• W4306398816 hasAuthorship W4306398816A5063389942 @default.
• W4306398816 hasAuthorship W4306398816A5082403692 @default.
• W4306398816 hasBestOaLocation W43063988161 @default.
• W4306398816 hasConcept C104819515 @default.
• W4306398816 hasConcept C121608353 @default.
• W4306398816 hasConcept C126322002 @default.
• W4306398816 hasConcept C126838900 @default.
• W4306398816 hasConcept C155672457 @default.
• W4306398816 hasConcept C171250308 @default.
• W4306398816 hasConcept C185592680 @default.
• W4306398816 hasConcept C192562407 @default.
• W4306398816 hasConcept C202751555 @default.
• W4306398816 hasConcept C2776428644 @default.
• W4306398816 hasConcept C2777807558 @default.
• W4306398816 hasConcept C2779723316 @default.

• next